INTRODUCTION
============

The inter-individual variation in analgesic response to opioids is well known. There is also a large inter-individual variability in constipation among both healthy volunteers^[@bib1]^ and cancer patients receiving opioids.^[@bib2]^ Constipation is a significant symptom among cancer patients receiving opioids, with prevalence rates ranging from 50 to 100% and with a potential to significantly impair the quality of life.^[@bib3],\ [@bib4],\ [@bib5]^ There is substantial evidence suggesting that treatment of constipation in this population can and should be improved. Still, constipation remains poorly recognized and undertreated.^[@bib6]^ Although laxatives are commonly prescribed, there is a surprising lack of evidence to guide the choice of treatment for the individual patient.^[@bib7]^

Constipation results from a lack of coordination between motility, mucosal transport, and defecation reflexes.^[@bib3],\ [@bib8]^ In normal bowel function, these mechanisms are finely adjusted via the enteric nervous system and a variety of gastrointestinal hormones constituting an intricate interplay between agonists, antagonists and receptors.^[@bib3],\ [@bib8]^ Based on available information about function, physiology, and bowel dysfunction, genetic variants within genes encoding serotonin receptors and associated proteins (*HTR3E*,^[@bib9],\ [@bib10],\ [@bib11],\ [@bib12]^ *HTR4*,^[@bib13]^ *HTR2A,*^[@bib14],\ [@bib15]^ and *TPH1*^[@bib16]^), α~2~ adrenergic receptors (*ADRA2A*^[@bib14],\ [@bib17]^), cholinergic receptors (*CHRM3*^[@bib18]^), substance P receptor (*TACR1*^[@bib14],\ [@bib19],\ [@bib20]^), cholecystokinin receptors (*CCKAR*^[@bib18],\ [@bib21],\ [@bib22],\ [@bib23]^), the ghrelin-obestatin preproprotein (*GHRL*^[@bib24]^), and the proto-oncogene c-kit (*KIT* ^[@bib25],\ [@bib26]^) are candidates to influence the presence and intensity of constipation in cancer patients.

Administration of opioids influences the enteric nervous system signaling, delays gastric emptying and intestinal transit, reduce gastrointestinal motility by suppressing the excitability and neurotransmitter release from enteric musculomotor neurones, and inhibit secretion, leading to opioid-induced constipation.^[@bib18]^ The interplay between opioids and bowel physiology is complex, but it has been shown that opioids and α~2-~adrenoceptor agonists have similar effects in the rat small intestine,^[@bib17]^ that opioid agonists affect intestinal motility by modulating cholinergic transmission,^[@bib18]^ inhibit release of substance P and block the presynaptic CCK-activated acetylcholine release.^[@bib18],\ [@bib19]^ Tryptophan hydroxylase 1 (TPH1) is known to increase in chronic constipation.^[@bib16]^ Chronic morphine administration increase c-Kit expression in bowel fragments of rats.^[@bib26]^ Selective 5-HT4 receptor agonists,^[@bib13]^ 5-HT2 receptor blockers and grehlin have been shown to improve opioid-induced constipation.^[@bib15],\ [@bib24]^ These observations in studies related to opioids and bowel function emphasize the potential influence of the candidate genes identified from factors involved in bowel function in general.

In addition to the genetic variants related to constipation mechanisms, genetic variants affecting the pharmacokinetic and pharmacodynamic properties of opioids may also lead to inter-individual variations in opioid response.^[@bib27]^ Genetic variations within genes encoding proteins involved in absorption, transport (*ABCB1*, adenosine triphosphate-binding cassette, subfamily B, member 1^[@bib28],\ [@bib29],\ [@bib30],\ [@bib31]^), metabolism (*COMT*, catechol-*O*-methyl transferase^[@bib32],\ [@bib33]^), elimination, receptor binding, and downstream signaling (*OPRM1/K1/D1* opioid receptors^[@bib3],\ [@bib34]^ and *ARRB2*, β-arrestin^[@bib34],\ [@bib35],\ [@bib36],\ [@bib37]^) may contribute to the inter-individual variations in constipation during opioid treatment.^[@bib3],\ [@bib27]^

There is a lack of knowledge about the causes of inter-individual differences in constipation during opioid treatment, although the association with cancer diagnosis, factors associated with opioid therapy and putative factors influencing the pathogenesis of constipation have been studied previously.^[@bib2],\ [@bib5],\ [@bib38],\ [@bib39]^ Increasing age and female gender,^[@bib4]^ overweight,^[@bib40]^ lower Karnofsky performance status,^[@bib39],\ [@bib41],\ [@bib42]^ hospitalization,^[@bib38]^ longer time on opioids, higher opioid dose,^[@bib5]^ certain opioid types,^[@bib14],\ [@bib43]^ certain cancer diagnoses,^[@bib4]^ presence of metastases,^[@bib38],\ [@bib39]^ and reduced mobility^[@bib42],\ [@bib44]^ are all among the proposed risk factors. However, most of these factors were found not to be significantly associated with the inter-individual variation in constipation in a clinically relevant sample of cancer patients receiving opioids.^[@bib2]^ Knowledge of factors associated with the variation in constipation may help to individualize treatment and avoid unnecessary patient suffering in the future. The present study aimed to identify possible genetic and non-genetic factors associated with the inter-individual variation in constipation among cancer patients receiving opioids.

METHODS
=======

Patients
--------

The European Pharmacogenetic Opioid Study included 2,294 patients receiving opioids for cancer pain, from 17 centers in 11 countries.^[@bib45]^ Included patients were 18 years or older, had a verified diagnosis of malignant disease, agreed to give a blood sample and had received scheduled opioid treatment corresponding to step III at the WHO analgesic ladder for at least 3 days.^[@bib46]^ Patients who lacked a basic proficiency of the language spoken in the study center were excluded. Because some chemotherapies cause constipation and others cause diarrhea,^[@bib2]^ patients receiving chemotherapy were excluded (*N*=353). For the analyses of genetic association we also excluded non-Caucasians (*N*=47) and Greek patients (*N*=5) to minimize heterogeneity. Samples in which no genomic DNA was available (*N*=20) or where all genotyping failed (*N*=2) and patients not answering the question about constipation (*N*=299) were also excluded. Finally, as all patients receiving step III opioids should have laxatives prescribed according to guidelines, we analyzed those receiving laxatives (*N*=806) and those not receiving laxatives (*N*=762) separately, as we did not know the reason for lack of laxative prescription.

The study was approved by ethical committees at each study center or in each country before initialization and performed according to the rules of the Helsinki-declaration. Written informed consent was obtained from all patients before inclusion.

Patients reported constipation and their need to stay in bed or a chair during the day by answering the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30).^[@bib47]^ The constipation intensity and extent of mobility during the past week were assessed on a four-point verbal rating scale with categories of "not at all, a little, quite a bit and very much". The exact questions were: "Have you been constipated?" for constipation and "Do you need to stay in bed or a chair during the day?" for mobility. Whole blood was drawn for pharmacogenetic analyses.

As prevalence and intensity of constipation might also be influenced by a number of non-genetic factors,^[@bib2],\ [@bib4],\ [@bib38],\ [@bib39],\ [@bib40],\ [@bib41],\ [@bib42]^ these were also registered to be included as covariates in the analyses of genetic association. Health-care providers (physician or nurse) registered age, gender, body mass index (BMI), time since start of opioids (months), opioid dose (total oral morphine equivalent daily dose in mg), cancer diagnosis, presence of metastasis, type of laxatives used during the past 24 h, type of opioid, affiliation to department, and country. In addition, the providers assessed Karnofsky performance status,^[@bib48]^ and cognitive function by the mini-mental state examination (MMSE).^[@bib49]^

SNP selection, genotyping and quality control
---------------------------------------------

Within 16 candidate genes, 88 putative single-nucleotide polymorphisms (SNPs) were selected based on a combination of associations identified in literature, available information in databases,^[@bib50],\ [@bib51],\ [@bib52],\ [@bib53]^ their frequency, functionality and their interrelated distance ([Supplementary Table 1](#sup1){ref-type="supplementary-material"} online). For SNP selection the SNP browser version 3.5 (Applied Biosciences, Foster City, CA, USA) was used to ensure that all selected SNPs had an expected allele frequency of 10% or more in Caucasians and that they were compatible with assay rules.

Isolation of genomic DNA from EDTA whole blood was performed at HUNT Biobank, Levanger, Norway by using the Gentra Puregene blood kit (QIAGEN Science, MA, USA). The SNPlex Genotyping Platform, including universal SNPlex System kits and reagents and SNP-specific ligation probes, was used (Applied Biosciences). Genotyping was performed according to the supplier\'s dry DNA protocol. The GeneMapper Software v4.0 (Applied Biosciences) and manual reading was used to analyze the SNPlex signals. Quality control and data cleaning was performed. Samples with low signals not separable from negative controls and samples in which \<90% of SNPs were genotyped were removed prior to analysis and treated as missing data. SNPs with a callrate \<90% and SNPs with inconsistent clustering on inspection were excluded from analyses.

Statistics
----------

Collection and organization of data was performed by The Pain and Palliation Research Group, Norwegian University of Science and Technology. The statistical software STATA version 11.0 was used for all analyses (StataCorp. 2009 *STATA Statistical Software: Release 11*. College Station, TX, USA: StataCorp LP).

Genotype frequencies, allele frequency and carriage were determined and quality checked. SNPs in which no genotypes were recorded, SNPs where genotypes were not in Hardy--Weinberg equilibrium (*X*^2^-test, *P*\<0.0005) and SNPs with an observed minor allele frequency (MAF) \<5% were rejected.

Univariate regressions (ordered logistic and linear) were performed to investigate the possible associations between non-genetic factors and intensity of constipation as reported in EORTC question 16. The factors explored were age, BMI, KPS, time on opioids, opioid dose, gender, type of laxative, mobility (as reported by EORTC question 4), type of opioid, department, metastases, and cancer diagnosis. Age, BMI, KPS, and opioid dose were analyzed both as continuous and as dichotomised variables (age ≤60 vs. \>60, BMI \<25 vs. ≥25, KPS ≤80 vs. \>80, dose≤300 mg vs. \>300 mg).^[@bib5]^ All factors significantly (*P*\<0.05) associated with constipation in univariate analyses were considered for inclusion as covariates in the stepwise multivariate analysis stratified by country. The identified non-genetic covariates were included in stratified multivariate regression analyses on the association between constipation and SNPs within the candidate genes related to the opioid- or constipation-signaling pathways (*HTR3E, HTR4, HTR2A, TPH1, ADRA2A, CHRM3, TACR1, CCKAR, KIT, ARRB2, GHRL, ABCB1, COMT, OPRM1, OPRK1*, and *OPRD1*). These ordered logistic regression analyses, with constipation as the dependent variable (scored 0 for "Not at all", 1 for "A little", 2 for "Quite a bit" and 3 for "Very much") generated β-slopes. Analyses were also repeated without the inclusion of covariates as a sensitivity check. Unstratified analyses, not including covariates, were used to compare symptom intensity between those carrying the "risk" allele and those not.

To mitigate the issue of multiple testing we used a 10% false discovery rate reporting the Benjamini--Hochberg (BH) thresholds, the constipation question of EORTC was pre-specified as the primary outcome and the codominant genetic model was prespecified for the primary analyses (dominant, recessive and additive models were exploratory). *P* values \<0.01 were interpreted as suggestive of effects that should be evaluated in future studies.

RESULTS
=======

Patients
--------

The demographic and disease-related characteristics of the 1,568 patients included in this study are shown in [Table 1](#tbl1){ref-type="table"}. Patients receiving laxatives were similar to those not receiving laxatives regarding age (mean 63 and 61 years), gender (59 and 49% male), BMI (24 and 23 kg/m^2^), KPS (60 and 63), mean MMSE total score,^[@bib27]^ time since diagnosis (31 months), presence of metastases (86 and 80%), cancer diagnoses represented, and type of opioids prescribed. There were more out-patients among those not receiving laxatives (29%), as compared with patients receiving laxatives (13%). Almost 80% were on stable dosing of opioids in both groups. "Quite a bit" or "very much" constipation was reported by 58% of patients receiving laxatives as compared with 32% among those not receiving laxatives.

Association with non-genetic factors
------------------------------------

In the univariate analyses, the results of ordered logistic and linear regressions were consistent. Five of the non-genetic factors were considered as significantly associated with the intensity of constipation ([Table 2](#tbl2){ref-type="table"}). These were type of laxative, mobility as measured by EORTC question 4 and whether the patient was an outpatient or admitted to a hospital among patients receiving laxatives (all *P*\<0.001). Karnofsky performance status (*P*=0.002) and presence of metastases (*P*=0.006) were associated with intensity of constipation among patients not receiving laxatives. In addition, the covariate "total daily opioid dose (mg)" had a *P* value of 0.024 in univariate analyses among patients treated with laxatives ([Table 2](#tbl2){ref-type="table"}). But as this covariate had coefficients that were not very consistent and reliable, was not a covariate among those not receiving laxatives and was not strongly prognostic when included in multivariate analyses (those underlying [Table 3](#tbl3){ref-type="table"}), it was dropped for further analyses (see also [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). The five significant factors were included as covariates in the multivariate regressions of genetic factors. The distributions of the responses for the EORTC constipation score in relation to the identified non-genetic factors are reported in [Table 3](#tbl3){ref-type="table"}.

Genotype distributions
----------------------

The success rates of genotyping and frequencies of genotypes and alleles are shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"} online. Out of the 88 candidate SNPs, 13 were excluded from analyses because of deviation from the Hardy--Weinberg equilibrium or a low observed MAF (\< 5%). These were rs34826744 in *HTR4*, rs13306143 and rs3750625 in *ADRA2A*, rs2237037 in *KIT*, rs16954146, and rs7208257 in *ARRB2*, rs34911341 in *GHRL*, rs1202181 in *ABCB1*, rs7815824 in *OPRK1*, rs1042114, rs204048, rs2234918, and rs204076 in *OPRD1*. The remaining 75 SNPs were further analyzed.

Association with genetic factors
--------------------------------

The non-genetic risk factors identified as statistically significant in [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"} were included in the multivariate analysis underlying [Tables 4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"}, where significant non-genetic risk factors were combined with genetic risk factors in a multivariable model. As shown in [Table 4](#tbl4){ref-type="table"}, the genetic factors associated with constipation among patients receiving laxatives were rs1800532 within *TPH1* in a codominant model, rs1799971 within *OPRM1* in additive and dominant models, as well as rs4437575 within *ABCB1* and rs10802789 within *CHRM3* in a dominant model (*P*\<0.01). None of these associations passed the BH criterion for a 10% false discovery rate. As shown in [Table 5](#tbl5){ref-type="table"}, the genetic factor associated with constipation among patients not receiving laxatives was rs2020917 within *COMT* in a codominant model. This association passed the BH criterion for a 10% false discovery rate.

More patients reported "quite a bit" or "very much" constipation among those not carrying the C-allele of rs1800532 in *TPH1* (64%) and those not carrying the G-allele of rs1799971 in *OPRM1* (63%). More patients reported "quite a bit" or "very much" constipation among those carrying the G-allele of rs4437575 in *ABCB1* (61%), the T-allele of rs10802789 in *CHRM3* (60%) or the T-allele of rs2020917 in *COMT* (36%).

DISCUSSION
==========

The inter-individual differences in constipation among patients receiving opioids are associated with the type of laxative administered, level of mobility, place of care, Karnofsky performance status, presence of metastases and five polymorphisms within *TPH1*, *OPRM1*, *ABCB1, CHRM3,* and *COMT* (*P*\<0.01).

The characteristics of included patients ([Table 1](#tbl1){ref-type="table"}) were as expected for cancer patients.^[@bib54]^ We found that 58% of patients receiving laxatives and 32% of patients not receiving laxatives reported "quite a bit" or "very much" constipation. These numbers indicate the large inter-individual variation in constipation among cancer patients receiving opioids, with some patients being constipated despite optimized treatment with laxatives and some not experiencing constipation despite high doses of opioids.^[@bib55]^

In agreement with other studies we observed that type of laxative,^[@bib56],\ [@bib57]^ hospitalization,^[@bib38]^ reduced mobility,^[@bib42],\ [@bib44]^ Karnofsky performance status,^[@bib41],\ [@bib42]^ and presence of metastases^[@bib38]^ influence whether a cancer patient report to experience constipation when receiving opioids.

The results of our study indicate that polymorphisms within *TPH1* may contribute to the inter-individual variations in constipation. Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in enterochromaffin (EC) cell 5-HT biosynthesis. Following luminal chemical and mechanical signals, the EC-cells release 5-HT, which stimulates 5-HT3 and 5-HT4 receptors on primary afferent neurons, inducing secretomotor and peristaltic reflexes of the intestines.^[@bib58]^ A common *TPH1* proximal promoter variant (rs7130929, −347C\>A) has been associated with the diarrheal subtype of irritable bowel syndrome (IBS).^[@bib59]^ Because of the distance to polymorphism rs1800532 (also known as 218A\>C, located in intron 7) it is difficult to compare the findings of this study with ours. A study among female, Caucasian IBS patients found no association between the diagnosis and five SNPs, including the rs1800532.^[@bib60]^

Our findings suggest that polymorphisms within *OPRM1* may be associated with intensity of constipation in cancer patients receiving opioids. The non-synonymous SNP rs1799971 in exon 1 (118A\>G, Asp40Asn) has repeatedly demonstrated a functional effect.^[@bib61]^ The effect on analgesia and pain sensitivity is extensively studied, with carriers of the minor 118G allele having a decreased analgesic response to morphine and M6G.^[@bib27]^ Interestingly, only a few of the 118A\>G-studies have addressed the association with intensity of constipation and no effect was found.^[@bib27]^ However, in these studies, constipation was only measured as a secondary outcome. In the preclinical setting carriage of the 118G allele is associated with lower levels of mu-opioid receptor mRNA and protein, higher potency and mu-opioid receptor affinity for beta-endorphin and lower potency for exogenous opioids.^[@bib61]^ Clinically, carriage of the 118G allele is associated with higher sensitivity to pain, a need for higher opioid doses to reach analgesic effect and an unchanged or lower risk of opioid-related side effects.^[@bib61]^ In agreement with this, we found that more patients reported "quite a bit" or "very much" constipation among those not carrying the G-allele of 118A\>G.

Polymorphisms within the *ABCB1* gene (also known as *MDR1*) may influence intensity of constipation as the product of this gene, P-glycoprotein, is a transporter of many drugs, including opioids. As for *OPRM1*, there are many studies addressing the influence of *ABCB1*-polymorphisms on pain sensitivity and opioid analgesia, but only a few on associations with opioid effects other than analgesia.^[@bib27]^ In a study prospectively recruiting 228 cancer patients receiving morphine, genetic variation in the *ABCB1* gene was associated with drowsiness, confusion, and hallucination.^[@bib62]^ No such association was observed with constipation. The polymorphism rs4437575 investigated in our study is located within the same haploblock as the more known 3435C\>T in exon 26 (rs1045642). In the present study more patients reported "quite a bit" or "very much" constipation among those carrying the minor G-allele of rs4437575. This finding is as expected, considering the strong linkage between rs4437575 and rs1045642, where carriage of the minor T-allele in the latter SNP is associated with more opioid-related side effects.^[@bib63]^

The results also indicated possible associations between SNPs in *CHRM3* and constipation in cancer patients receiving opioids. Cholinergic muscarine receptor 3 (CHRM3) is found in the intestinal wall,^[@bib64]^ and CHRM3 antagonists have been shown to inhibit intestinal motility.^[@bib65]^ Genetic variation within the *CHRM3* gene (rs3738435) has been tested for an association with IBS and specifically for an association with the constipation subtype, but no such associations were found.^[@bib66]^ The SNP rs10802789, also known as c.-249-8806C \> T, has been associated with intensity of nausea/vomiting in a previous study.^[@bib67]^ To our knowledge, the exact functional consequence of this polymorphism is still unknown.

The association between constipation and rs2020917 in *COMT* among cancer patients not receiving laxatives passed the BH criterion. More patients reported "quite a bit" or "very much" constipation among those carrying the T-allele of rs2020917 in *COMT* (36%). The variant rs2020917 is located in the 5′ regulatory promoter of the membrane-bound-COMT isoform and it has been shown to alter nuclear protein binding patterns, thereby upregulating transcription and possibly increasing COMT enzyme activity.^[@bib68]^ On the contrary, it has also been demonstrated that the haploblock containing the T-allele of rs2020917 and the C-allele of the nearby rs737865 is associated with reduced *COMT*-transcription.^[@bib69]^ Decreased enzyme-activity, as coded by the Met-allele of the Val158Met (rs4680) variant has been associated with enhanced activation of dopaminergic neurotransmission and lower opioid-dose requirement.^[@bib70]^ In animal models, chronic activation of dopaminergic neurotransmission reduces the neuronal content of enkephalin peptides,^[@bib71]^ leading to an upregulation of mu-opioid receptors.^[@bib72]^ Taken together, our finding agrees with the existing literature on lower opioid-dose requirements and possibly increased adverse effects associated with reduced *COMT*-transcription and enzyme-activity.

There are several challenges of candidate gene association research, and we recognize some in the present study. First, there is a lack of a stringent definition of constipation among cancer patients receiving opioids. Hence, comparison of results between studies is difficult and there is no agreement on definition of the phenotype.^[@bib73]^ This study, including more patients than other studies addressing genetic variability related to opioid effects, utilized the EORTC QLQ-C30, a well-validated assessment tool, formally translated into many languages to define the phenotype. Other studies may also include objective measures such as number of stools and similar outcomes. Second, symptom intensity was registered for the past week, whereas administration of laxatives was registered for the past 24 h. However, we believe use of laxatives was related to symptom intensity as assessments for the past 24 h and the past week are closely related in cancer patients.^[@bib74]^ Third, this study did not take into consideration gene--gene interactions, gene--environment interactions or epigenetics. However, genetic features in favor of the present study are that genes and polymorphisms were chosen based on known biology and pathophysiology, population stratification was avoided by only including Caucasians, measures have been undertaken to control for false positive findings, more than a few candidate SNPs were included in the analyses, and potential clinical confounding factors were identified and included in the analyses. Finally, as no replication sample was included, the findings should be repeated in an independent study before the associations could be regarded as conclusive.

CONCLUSION
==========

This study suggests that type of laxative, mobility, hospitalization, Karnofsky performance status, presence of metastases and five SNPs within *TPH1*, *OPRM1*, *ABCB1*, *CHRM3,* and *COMT* are associated with the variability in constipation among cancer patients treated with opioids (*P*\<0.01). Only rs2020917 in *COMT* passed the BH criterion for a 10% false discovery rate. Genetic associations can be helpful to elucidate the relevant biological mechanisms for constipation in patients treated with opioids. These biological mechanisms can therefore be identified as targets for developing new and improved therapy for constipation in patients receiving opioids. Before introduction of genetic testing in routine patient care, large prospective studies are needed to determine whether genetic testing of polymorphisms helps to predict the risk and treatment of constipation among cancer patients receiving opioids, and whether this is a cost-effective approach.

Study Highlights
================
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###### Patient demographics

                                                   ***Laxatives (*****N*****=806)***   ***No laxatives (*****N*****=762)***           
  ------------------------------------------------ ----------------------------------- -------------------------------------- ------- -------
  *Age (years)*                                    63.1                                11.9                                   60.6    12.1
  *Body mass index (kg/m^2^)*                      23.8                                4.6                                    23.3    4.6
  *Karnofsky performance status (range 0--100)*    60.0                                16.2                                   62.7    16.6
  *Mini mental state, total score (range 0--30)*   26.7                                3.5                                    27.2    3.0
  *Time since diagnosis (months)*                  31.1                                44.8                                   30.6    44.2
                                                                                                                                       
                                                   **N**                               **%**                                  **N**   **%**
  *Gender*                                                                                                                            
   Female                                          333                                 41.3                                   390     51.2
   Male                                            473                                 58.7                                   372     48.8
                                                                                                                                       
  *Department*                                                                                                                        
   Palliative care unit/hospice                    272                                 33.7                                   226     29.7
   General oncology ward                           424                                 52.6                                   278     36.5
   Surgical ward                                   7                                   0.9                                    35      4.6
   Out-patients                                    103                                 12.8                                   223     29.3
                                                                                                                                       
  *Status of opioid treatment*                                                                                                        
   Opioid recently initiated/titration             158                                 19.6                                   140     18.4
   Stable dosing                                   642                                 79.7                                   616     80.8
                                                                                                                                       
  *Metastases*                                                                                                                        
   None                                            114                                 14.1                                   156     20.5
   One or more                                     692                                 85.9                                   606     79.5
                                                                                                                                       
  *Cancer diagnosis*                                                                                                                  
   Breast                                          88                                  10.9                                   81      10.6
   Female reproductive organs                      48                                  6.0                                    79      10.4
   Gastrointestinal                                140                                 17.4                                   192     25.2
   Hematological                                   38                                  4.7                                    39      5.1
   Head and neck                                   34                                  4.2                                    62      8.1
   Lung                                            173                                 21.5                                   113     14.8
   Prostate                                        131                                 16.3                                   60      7.9
   Urological                                      60                                  7.4                                    53      7.0
   Other or unknown                                128                                 15.9                                   114     15.0
                                                                                                                                       
  *Type of opioid*                                                                                                                    
   Morphine                                        366                                 45.4                                   254     33.3
   Oxycodone                                       189                                 23.4                                   144     18.9
   Fentanyl                                        174                                 21.6                                   277     36.4
   Other                                           77                                  9.6                                    87      11.4
                                                                                                                                       
  *Country*                                                                                                                           
   Denmark                                         10                                  1.2                                    18      2.4
   Finland                                         8                                   1.0                                    17      2.2
   Germany                                         111                                 13.8                                   128     16.8
   Iceland                                         65                                  8.1                                    50      6.6
   Italy                                           116                                 14.4                                   191     25.1
   Lithuania                                       0                                   0                                      41      5.4
   Norway                                          271                                 33.6                                   130     17.1
   Sweden                                          29                                  3.6                                    78      10.2
   Switzerland                                     64                                  7.9                                    20      2.6
   United Kingdom                                  132                                 16.4                                   89      11.7
                                                                                                                                       
  *Laxative treatment*                                                                                                                
   Bulk                                            376                                 46.7                                            
   Stimulant                                       175                                 21.7                                            
   Combination and/or other                        253                                 31.4                                            
                                                                                                                                       
  *EORTC 16 Constipation*                                                                                                             
   Not at all                                      160                                 19.9                                   327     42.9
   A little                                        180                                 22.3                                   194     25.5
   Quite a bit                                     233                                 28.9                                   153     20.1
   Very much                                       233                                 28.9                                   88      11.5

EORTC 16, European Organization for Research and Treatment of Cancer Core Quality of Life Question number 16.

###### Non-genetic factors associated with constipation in univariate analyses

                                                                                                 ***Receiving laxatives (*****N*****=806)***    ***No laxatives (*****N*****=762)***                                           
  ---------------------------------------------------------------------------------------------- --------------------------------------------- -------------------------------------- --------- ---------- ------------------- ---------
  *Age (years)*                                                                                                                                                                                                                 
  ≤ 60 (0)                                                                                       *0.003*                                                 *−0.003 to 0.009*            *0.339*   *0.004*     *−0.002 to 0.010*  *0.187*
  \>60 (1)                                                                                       0.084                                                    −0.070 to 0.239             0.284     0.115        −0.033 to 0.264   0.128
                                                                                                                                                                                                                                
  *BMI (kg/m^2^)*                                                                                                                                                                                                               
  \<25 (0)                                                                                       *−0.007*                                                *−0.024 to 0.010*            *0.402*   *−0.000*    *−0.016 to 0.016*  *0.997*
  ≥25 (1)                                                                                        0.022                                                    −0.141 to 0.185             0.794     −0.066       −0.228 to 0.096   0.424
                                                                                                                                                                                                                                
  *KPS (range 0--100)*                                                                                                                                                                                                          
  ≤ 80 (0)                                                                                       *−0.001*                                                *−0.005 to 0.004*            *0.776*   *−0.003*    *−0.008 to 0.001*  *0.171*
  \>80 (1)                                                                                       −0.381                                                   −0.763 to −0.000            0.050     −0.457      −0.750 to −0.164   0.002
                                                                                                                                                                                                                                
  *Time since start opioids*                                                                     −0.048                                                   −0.106 to 0.010             0.108     0.048        −0.009 to 0.104   0.101
  *Total daily dose (g)*                                                                         0.141                                                    −0.264 to −0.019            0.024     0.148        −0.033 to 0.328   0.109
                                                                                                                                                                                                                                
  *Gender*                                                                                                                                                                                                                     
  Male (0), female (1)                                                                           0.104                                                    −0.050 to 0.258             0.185     −0.079       −0.228 to 0.070   0.298
                                                                                                                                                                                                                                
  *Type of opoid*                                                                                                                                                                                                              
  Morphine (0=no, 1=yes), oxycodone (0=no, 1=yes), fentanyl (0=no, 1=yes), other (0=no, 1=yes)   −0.042                                                   −0.277 to 0.193             0.725     −0.138       −0.315 to 0.039   0.127
                                                                                                                                                                                                                               
  *Metastases*                                                                                                                                                                                                                 
  None (0), ≥ one (1)                                                                            0.167                                                    −0.049 to 0.382             0.129     0.259        0.076 to 0.441    0.006
                                                                                                                                                                                                                                
  *Cancer diagnosis*                                                                                                                                                                                                            
  Other (0), gastrointestinal or female reproductive organs (1)                                  −0.116                                                   −0.295 to 0.063             0.203     −0.096       −0.252 to 0.059   0.225
                                                                                                                                                                                                                               
  *Laxative treatment*                                                                                                                                                                                                         
  Bulk (0=no, 1=yes), stimulant (0=no, 1=yes), combination and/or other (0=no, 1=yes)            0.212                                                     0.126 to 0.297             \<0.001                                   
                                                                                                                                                                                                                               
  *Reduced mobility*                                                                                                                                                                                                           
  Not at all, a little, quite a bit, very much                                                   0.178                                                     0.100 to 0.256             \<0.001   −0.001       −0.077 to 0.075   0.979
                                                                                                                                                                                                                               
  *Department*                                                                                                                                                                                                                 
  Outpatient (0), hospitalized (1)                                                               0.533                                                     0.309 to 0.757             \<0.001   −0.079       −0.242 to 0.085   0.345

BMI, body mass index; CI, confidence interval; KPS, Karnofsky performance status.

Results of linear regression. The results of ordered logistic regression (not shown) were closely similar. The dependent variable, constipation, was scored as 0 for "Not at all", 1 for "A little", 2 for "Quite a bit", and 3 for "Very much". Note: analyses were stratified by country. Age, BMI, and KPS were investigated both as continuous and as dichotomous variables.

###### Non-genetic factors associated with constipation in multivariate analyses

                         ***Receiving laxatives (*****N*****=806)***        ***No laxatives (*****N*****=762)***                                                                                                    
  ---------------------- --------------------------------------------- ---- -------------------------------------- ---- ----- ---- ----- ---- ----- -------------- ----- ---- ----- ---- ----- ---- ---- ---- ----- --------------
  *KPS (range 0--100)*                                                                                                                                                                                                  0.536
   ≤80 (0)                                                                                                                                                         299   42   176   25   147   21   88   12   710    0.318--0.906
   \>80 (1)                                                                                                                                                        28    54   18    35   6     12   0    0    52        0.020
                                                                                                                                                                                                                           
  *Metastases*                                                                                                                                                                                                          1.599
   None (0)                                                                                                                                                        86    55   33    21   22    14   15   10   156    1.139--2.243
   ≥ one (1)                                                                                                                                                       241   40   161   27   131   22   73   12   606       0.007
                                                                                                                                                                                                                           
  *Laxative treatment*                                                                                                                                                                                                     
   Bulk                  88                                            23   98                                     26   96    26   94    25   376   0.426                                                                  
   Stimulant             34                                            19   42                                     24   66    38   33    19   175   0.273--0.579                                                           
   Combination/other     38                                            15   39                                     15   71    28   105   42   253   \<0.001                                                                
                                                                                                                                                                                                                           
  *Reduced mobility*                                                                                                                                                                                                       
   Not at all            27                                            36   23                                     30   15    20   11    14   76    0.272                                                                  
   A little              42                                            25   34                                     20   39    23   52    31   167   0.134--0.409                                                           
   Quite a bit           43                                            15   69                                     25   95    34   73    26   280   \<0.001                                                                
   Very much             48                                            17   53                                     19   82    29   97    35   280                                                                          
                                                                                                                                                                                                                           
  Department                                                                                                                                        0.906                                                                  
   Outpatient (0)        34                                            33   29                                     28   25    24   15    15   103   0.524--1.287                                                           
   Hospitalized (1)      126                                           18   151                                    21   208   30   218   31   703   \<0.001                                                                

BMI, body mass index; CI, confidence interval; KPS, Karnofsky performance status.

Results of linear regression. The results of ordered logistic regression (not shown) were closely similar. The dependent variable, constipation, was scored as 0 for "Not at all", 1 for "A little", 2 for "Quite a bit", and 3 for "Very much". Because of a few missing values, some counts does not add up to 100%.

###### Genetic factors possibly associated with constipation among patients receiving laxatives (*N*=806)

  ***Gene***    **Genotype**   ***Absolute number of patients***   ***Multivariate analysis***   **P** ***value alleles***[a](#t4-fn3){ref-type="fn"}                                                                                            
  ------------- -------------- ----------------------------------- ----------------------------- ------------------------------------------------------ ------ ------- ------ ------- ------ ------- ------- -------------- ------- ------------ ---------
  *TPH1*                                                                                                                                                                                                                                         
   rs1800532    AA             26                                  20                            21                                                     16     36      27     48      37     131                                                  
                AC             85                                  22                            93                                                     25     101     27     99      26     378     1.457    1.126--1.885  0.004   Codominant    
                CC             42                                  16                            59                                                     22     87      33     79      30     267                                                  
                *C*            *127*                               *20*                          *152*                                                  *24*   *188*   *29*   *178*   *28*   *645*                                               *0.094*
                *Not C*        *26*                                *20*                          *21*                                                   *16*   *36*    *27*   *48*    *37*   *131*                                                
                                                                                                                                                                                                                                                  
  *OPRM1*                                                                                                                                                                                                                                        
   rs1799971    AA             84                                  17                            97                                                     20     150     31     152     31     483     0.664    0.500--0.882  0.005   Additive      
                AG             35                                  22                            44                                                     28     40      26     37      24     156     1.523    1.110--2.090  0.009   Dominant      
                GG             2                                   25                            3                                                      38     2       25     1       13     8                                                    
                *G*            *37*                                *23*                          *47*                                                   *29*   *42*    *26*   *38*    *23*   *164*                                               *0.005*
                *Not G*        *84*                                *17*                          *97*                                                   *20*   *150*   *31*   *152*   *31*   *483*                                                
                                                                                                                                                                                                                                                  
  *ABCB1*                                                                                                                                                                                                                                        
   rs4437575    AA             60                                  24                            60                                                     24     64      26     65      26     249     0.687    0.520--0.908  0.008   Dominant      
                AG             64                                  17                            92                                                     24     117     31     107     28     380                                                  
                GG             31                                  20                            23                                                     15     46      30     53      35     153                                                  
                *G*            *95*                                *18*                          *115*                                                  *22*   *163*   *31*   *160*   *30*   *533*                                               *0.028*
                *Not G*        *60*                                *24*                          *60*                                                   *24*   *64*    *26*   *65*    *26*   *249*                                                
                                                                                                                                                                                                                                                  
  *CHRM3*                                                                                                                                                                                                                                        
   rs10802789   CC             46                                  22                            52                                                     25     61      30     46      22     205     0.667    0.497--0.896  0.007   Dominant      
                CT             53                                  16                            75                                                     23     102     31     101     31     331                                                  
                TT             25                                  18                            31                                                     23     38      28     42      31     136                                                  
                *T*            *78*                                *17*                          *106*                                                  *23*   *140*   *30*   *143*   *31*   *467*                                               *0.013*
                *Not T*        *46*                                *22*                          *52*                                                   *25*   *61*    *30*   *46*    *22*   *205*                                                
                                                                                                                                                                                                                                                  
  *COMT*                                                                                                                                                                                                                                         
   rs2020917    CC             55                                  17                            66                                                     20     100     31     103     32     324                                                  
                CT             59                                  22                            60                                                     23     77      29     69      26     265     1.202    0.903--1.601  0.207   Codominant    
                TT             9                                   15                            19                                                     32     14      24     17      29     59                                                   
                *T*            *68*                                *21*                          *79*                                                   *24*   *91*    *28*   *86*    *27*   *324*                                               *0.042*
                *Not T*        *55*                                *17*                          *66*                                                   *20*   *100*   *31*   *103*   *32*   *324*                                                

CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.

The odds ratios are from ordered logistic regression with constipation as the dependent variable, scored as 0 for "Not at all", 1 for "A little", 2 for "Quite a bit", and 3 for "Very much". Because of a few missing values, some counts does not add up to 100%.

*P* value of unstratified analyses without the inclusion of covariates.

*P* values of ordered logistic regression in the analyses allowing for covariates and stratified by country.

###### Genetic factors possibly associated with constipation among patients not receiving laxatives (*N*=762)

  ***Gene***    **Genotype**   ***Absolute number of patients (%)***   ***Multivariate analysis***   **P** ***value alleles***[a](#t5-fn3){ref-type="fn"}                                                                                                 
  ------------- -------------- --------------------------------------- ----------------------------- ------------------------------------------------------ ------ ------- ------ ------ ------ ------- ------- -------------- ------------- ------------ ---------
  *TPH1*                                                                                                                                                                                                                                                  
   rs1800532    AA             40                                      38                            28                                                     27     20      19     17     16     105                                                        
                AC             158                                     43                            91                                                     25     72      20     44     12     365     1.009    0.775--1.315  0.945         Codominant    
                CC             120                                     44                            68                                                     25     59      22     25     9      272                                                        
                *C*            *278*                                   *44*                          *159*                                                  *25*   *131*   *21*   *69*   *11*   *637*                                                     *0.209*
                *Not C*        *40*                                    *38*                          *28*                                                   *27*   *20*    *19*   *17*   *16*   *105*                                                      
                                                                                                                                                                                                                                                           
  *OPRM1*                                                                                                                                                                                                                                                 
   rs1799971    AA             207                                     42                            129                                                    26     106     21     56     11     498     1.013    0.758--1.353  0.932         Additive      
                AG             50                                      41                            27                                                     22     31      25     15     12     123     0.960    0.676--1.363  0.820         Dominant      
                GG             6                                       40                            5                                                      33     3       20     1      7      15                                                         
                *G*            *56*                                    *41*                          *32*                                                   *23*   *34*    *25*   *16*   *12*   *138*                                                     *0.632*
                *Not G*        *207*                                   *42*                          *129*                                                  *26*   *106*   *21*   *56*   *11*   *498*                                                      
                                                                                                                                                                                                                                                           
  *ABCB1*                                                                                                                                                                                                                                                 
   rs4437575    AA             102                                     46                            48                                                     22     48      22     23     10     221                                                        
                AG             147                                     39                            98                                                     26     81      22     47     13     373     0.867    0.645--1.165  0.345         Dominant      
                GG             71                                      47                            41                                                     27     23      15     16     11     151                                                        
                *G*            *281*                                   *54*                          *139*                                                  *27*   *104*   *20*   *63*   *12*   *524*                                                     *0.425*
                *Not G*        *102*                                   *46*                          *48*                                                   *22*   *48*    *22*   *23*   *10*   *221*                                                      
                                                                                                                                                                                                                                                           
  *CHRM3*                                                                                                                                                                                                                                                 
   rs10802789   CC             80                                      41                            50                                                     26     38      19     28     14     196                                                        
                CT             131                                     46                            69                                                     24     54      19     32     11     286     1.119    0.816--1.534  0.484         Dominant      
                TT             46                                      42                            25                                                     23     26      24     12     11     109                                                        
                *T*            *177*                                   *45*                          *94*                                                   *24*   *80*    *20*   *44*   *11*   *395*                                                     *0.321*
                *Not T*        *80*                                    *41*                          *50*                                                   *26*   *38*    *19*   *28*   *14*   *196*                                                      
                                                                                                                                                                                                                                                           
  *COMT*                                                                                                                                                                                                                                                  
   rs2020917    CC             143                                     47                            70                                                     23     64      21     28     9      305     0.606    0.454--0.809  **\<0.001**   Codominant    
                CT             100                                     35                            78                                                     27     66      23     42     15     286                                                        
                TT             27                                      55                            11                                                     22     9       18     2      4      49                                                         
                *T*            *127*                                   *38*                          *89*                                                   *27*   *75*    *22*   *44*   *13*   *335*                                                     *0.024*
                *Not T*        *143*                                   *47*                          *70*                                                   *23*   *64*    *21*   *28*   *9*    *305*                                                      

CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.

The odds ratios are from ordered logistic regression with constipation as the dependent variable, scored as 0 for "Not at all", 1 for "A little", 2 for "Quite a bit", and 3 for "Very much". Because of a few missing values, some counts does not add up to 100%.

*P* value of unstratified analyses without the inclusion of covariates

*P* values of ordered logistic regression in the analyses allowing for covariates and stratified by country. Associations in **bold** passed the Benjamini--Hochberg criterion for selection requiring a 10% false discovery rate correction for multiple testing.
